← Library
Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Noopept

Not FDA approved

Synthetic nootropic dipeptide

Also known as: omberacetam, GVS-111, Omberacetam, J759.455K, omberacetamum, ethyl (2-phenylacetyl)-L-prolylglycinate, ethyl 1-(phenylacetyl)-L-prolylglycinate

Evidence score
21/ 100
Thin evidence

Very thin human evidence

  • Regulatory standing. Sold as a research chemical, not approved
  • Animal / preclinical only. Evidence is largely animal or in-vitro
  • No registered human trials. Nothing registered on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Noopept, also called omberacetam or GVS-111, is a synthetic dipeptide-derived compound developed in Russia and often grouped with racetam-style nootropics. It is thought to act partly through its metabolite cycloprolylglycine and has been studied for effects on neurotrophic factors such as BDNF and NGF and on glutamate and acetylcholine signaling, mainly in laboratory and animal models.

What the evidence shows

Automatic summaryAnimal / preclinical

It is not FDA-approved and has no registered human trials in the gathered data. Most of the roughly 86 published papers are preclinical, with only a few small clinical studies, mostly from Russia, so any cognitive benefit in humans is not established.

Key facts

Molecular formula
C17H22N2O4
Molecular weight
318.4 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies
Nonemost advanced phase
0completed (sample)
0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

86papers referencing Noopept

GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons.

Int J Dev Neurosci2003

The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.

J Psychopharmacol2007

Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats.

Mol Neurobiol2021

Characterization and prebiotic potential of polysaccharides from Rosa roxburghii Tratt pomace by ultrasound-assisted extraction.

Int J Biol Macromol2024

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.